newsfilter
← Latest News
GlobeNewswire·

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH)